Article
Oncology
Jing Xu, Yi Gao, Xiaotian Luan, Ke Li, Jing Wang, Yilin Dai, Mingyi Kang, Chong Lu, Minhua Zhang, Chris X. Lu, Yu Kang, Congjian Xu
Summary: The combination of AKT inhibitor and PARP inhibitor shows anti-tumor effects in recurrent ovarian cancer patients. AKT inhibition enhances the sensitivity of tumor cells to PARP inhibition and reduces the activity of PARP enzymes or the expression level of PARP1 protein.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2022)
Article
Oncology
G. E. Konecny, A. E. Wahner Hendrickson, T. M. Davidson, B. J. Winterhoff, S. Ma, S. Mahner, J. Sehouli, P. A. Fasching, G. Feisel-Schwickardi, M. Poelcher, L. D. Roman, A. Rody, B. Y. Karlan, S. A. Mullany, H. Chen, I. L. Ray-Coquard, D. M. Provencher, A. Yachnin, P. H. Cottu, J. A. Glaspy, P. Haluska, D. J. Slamon
Summary: This study investigated the efficacy and safety of adding ganitumab to CP chemotherapy in primary EOC patients, but did not show improvement in PFS. The results do not support further study of ganitumab in unselected EOC patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Farasat Kazmi, Shibani Nicum, Rene L. Roux, Laura Spiers, Chat Gnanaranjan, Ajithkumar Sukumaran, Hani Gabra, Essam Ghazaly, Nigel W. McCracken, David J. Harrison, Sarah P. Blagden
Summary: The combination of NUC-1031 and carboplatin is well tolerated in recurrent ovarian cancer, with the highest efficacy observed in the NUC-1031 dose cohort of 500 mg/m(2) administered on days 1 and 8 with AUC5 carboplatin. This therapeutic combination remains attractive even in patients with platinum-resistant disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Wesley C. C. Burkett, Ziyi Zhao, Meredith A. A. Newton, Wenchuan Sun, Boer Deng, Angeles Alvarez Secord, Chunxiao Zhou, Victoria Bae-Jump
Summary: The combination of IPAT and carboplatin showed better anti-tumor activity in USC cells compared to IPAT or carboplatin alone. The combination treatment led to reduced proliferation, induced apoptosis and caused cellular stress. In addition, it also reduced cell adhesion and inhibited cell invasion.
ANNALS OF MEDICINE
(2023)
Article
Oncology
Tamar Safra, Barliz Waissengrin, Talya Levy, Ellie Leidner, Rotem Merose, Diana Matceyevsky, Dan Grisaru, Ido Laskov, Nadav Mishaan, Rotem Shayzaf, Ido Wolf
Summary: The study compared the efficacy and safety of the traditional PC-3W regimen with the modified PC-W regimen for ovarian cancer treatment, finding that PC-W had better median progression-free survival and overall survival compared to PC-3W, with fewer adverse effects. It showed a better safety profile, particularly suitable for elderly or frail patients.
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Makio Shozu
Summary: The study evaluated the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy in patients with ovarian cancer who developed carboplatin hypersensitivity reaction. The majority of patients were able to complete the treatment without hypersensitivity reactions, and the therapy was found to be well-tolerated and effective for most patients.
Article
Oncology
Naohiro Takeshita, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Nobukazu Tanaka, Ryutaro Onaga, Yuta Hoshi, Shingo Sakashita, Genichiro Ishii, Makoto Tahara
Summary: The treatment sequence of PCE followed by nivolumab shows promising survival outcomes for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. PCE induces rapid tumor response, and the addition of nivolumab extends overall survival regardless of combined positive score.
Article
Oncology
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Summary: The purpose of this study was to assess the safety, recommended dose, pharmacokinetic profile, and clinical activity of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine in patients with advanced solid tumors. The results showed that the combination of SRA737 and low-dose gemcitabine was well tolerated and demonstrated tumor responses in anogenital cancer and other solid tumors.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Richard T. Penson, Allison J. Ambrosio, Christin A. Whalen, Carolyn N. Krasner, Panagiotis A. Konstantinopoulos, Charles Bradley, Ursula A. Matulonis, Michael J. Birrer
Summary: This article evaluates the potential efficacy of iniparib in combination with gemcitabine and carboplatin in platinum-sensitive ovarian cancer. The results show that the overall response rate was 66% in platinum-sensitive disease and 26% in platinum-resistant disease. Notably, 93% of the patients experienced clinical benefit, with 41.2% achieving CA125 response without tumor shrinkage.
Article
Oncology
Sileny N. Han, Amit Oza, Nicoletta Colombo, Ana Oaknin, Francesco Raspagliesi, Robert M. Wenham, Elena Ioana Braicu, Andrea Jewell, Vicky Makker, Jonathan Krell, Eva Maria Guerra Alia, Jean-Francois Baurain, Zhenqiang Su, Rachel Neuwirth, Sylvie Vincent, Farhad Sedarati, Douglas Faller, Giovanni Scambia
Summary: This phase 2 study investigated the efficacy of sapanisertib in the treatment of endometrial cancer. The results showed that the combination of sapanisertib and paclitaxel prolonged the median progression-free survival compared to paclitaxel alone, but the difference was not statistically significant. The two treatment regimens also differed in terms of treatment-emergent adverse event rates.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Maria Rubinstein, Sherry Shen, Bradley J. Monk, David S. P. Tan, Angelica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker
Summary: Incidence and mortality of endometrial cancer are increasing among all ethnic groups. Carboplatin plus paclitaxel is the frontline treatment, but subsequent traditional cytotoxic chemotherapy is challenging. Molecular characterization has led to the development of precision immunotherapies and targeted therapies. The applicability of platinum rechallenge is subjective and limited by small retrospective studies.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Heling Zhang, Ye Zhang
Summary: The combination of olaparib and paclitaxel with carboplatin improves the efficacy, serum indexes, and reduces the recurrence rate of ovarian cancer without significant toxic side effects.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2022)
Article
Oncology
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone
Summary: This study compared carboplatin and paclitaxel with avelumab plus carboplatin and paclitaxel as first-line treatment in patients with advanced or recurrent endometrial cancer. The addition of avelumab showed potential for improving progression-free survival, but further investigation is needed.
Article
Oncology
Linda Ye, Mihitha Ariyapperuma, Angela Jacques, Tarek Meniawy, Michael Millward
Summary: The study found that approximately one third of early-phase clinical trial patients required hospitalization, most commonly due to cancer-related complications. Hospitalizations were associated with treatment response and trial duration, but not with patient age, sex, tumor type, or trial drug.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Leslie Calapre, Tindaro Giardina, Aaron B. B. Beasley, Anna L. L. Reid, Colin Stewart, Benhur Amanuel, Tarek M. M. Meniawy, Elin S. S. Gray
Summary: This study compared the suitability of the Accel and Oncomine panels for identification of TP53 mutations in ctDNA of HGSOC patients. Results showed that only 60% of patients were found to have TP53 mutations using the Accel panel, but the addition of molecular tags in the Oncomine panel improved ctDNA detection with at least one mutation detected in all cases. Orthogonal validation using droplet digital PCR confirmed 79% of the identified mutations. Overall, the Oncomine panel with unique molecular identifiers (UMI) appears more useful for ctDNA analysis in HGSOC.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill
Summary: Until recently, the outcome for women with advanced endometrial carcinoma has been poor. New immune therapies have improved outcomes for some women, but determining which women will respond is important. This study aimed to find markers to better predict response to immunotherapy. Tumor-associated inflammatory cells were found to have the strongest association with response. A novel algorithm using optimal cutoff points was able to identify non-responders with high sensitivity. Further validation is needed.
Article
Oncology
Jayesh Desai, Peter Fong, Victor Moreno, Sophia Frentzas, Tarek Meniawy, Ben Markman, Mark Voskoboynik, Tahmina Rahman, Nageshwar Budha, John Wu, Jin Marlow, Silu Yang, Emiliano Calvo, Juan Martin-Liberal
Summary: This study investigated the safety and anti-tumor activity of BGB-A333, a PD-L1 inhibitor, alone and in combination with tislelizumab in patients with advanced solid tumors. The results showed that BGB-A333 in combination with tislelizumab demonstrated promising anti-tumor activity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Christelle Schofield, Pedro Lopez, Paul A. Cohen, Dennis R. Taaffe, Robert Usher Newton, Daniel A. Galvao, Emily Jeffery, Tarek M. Meniawy, Carolyn J. Peddle-McIntyre
Summary: The study aimed to compare muscle morphology in patients who underwent different surgeries for advanced high-grade serous ovarian cancer and explore the associations with survival outcomes. Skeletal muscle index and density were calculated using CT images of 88 ovarian cancer patients. Results showed that low skeletal muscle index and density were prevalent at diagnosis, with interval surgery patients having significantly lower mean skeletal muscle density than primary surgery patients. Greater reductions in skeletal muscle density during treatment were associated with poorer overall survival. Therefore, supportive care involving resistance exercise and nutrition counseling may help preserve/enhance muscle mass and density.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, Tarek M. Meniawy, Michele Del Vecchio, Celeste Lebbe, Michele Guida, Caroline Dutriaux, Brigitte Dreno, Nicolas Meyer, Pier Francesco Ferrucci, Stephane Dalle, Muhammad Adnan Khattak, Jean-Jacques Grob, Karen Briscoe, James Larkin, Sandrine Mansard, Thierry Lesimple, Massimo Guidoboni, Silvia Sabatini, Erika Richtig, Rudolf Herbst, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Michele Maio
Summary: The study aimed to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in patients with advanced melanoma. It found that the treatment was tolerable and had similar efficacy in all treated population with various subgroups, but reduced efficacy in patients with specific characteristics, indicating a need for novel treatment options.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Genevieve Dall, Cassandra J. J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedo, Jocelyn Penington, Matthew J. J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. L. Kyran, Emily O'Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. P. Ng, Alexander Dobrovic, Stephen B. B. Fox, Orla McNally, Jeremy D. D. Power, Tarek Meniawy, Teng Han Tan, Ian M. M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. T. Papenfuss, Clare L. L. Scott, Holly E. E. Barker
Summary: This study identified mutations in DNA repair genes in a subset of uterine leiomyosarcoma patients and found that these patients may benefit from PARP inhibitor therapy. Patient-derived xenograft models confirmed the efficacy of this treatment approach.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Christelle Schofield, Robert U. Newton, Dennis R. Taaffe, Daniel A. Galvao, Paul A. Cohen, Tarek M. Meniawy, Carolyn J. Peddle-McIntyre
Summary: Resistance exercise after first-line treatment in ovarian cancer survivors improves muscle mass and density, muscle strength, physical function, and quality of life without negative effects on pelvic floor symptoms. Larger studies are needed to confirm these benefits in supportive care for ovarian cancer.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Brendan J. Crosby, Robert U. Newton, Daniel A. Galvao, Dennis R. Taaffe, Pedro Lopez, Tarek M. Meniawy, Muhammad A. Khattak, Wei-Sen Lam, Elin S. Gray, Favil Singh
Summary: The purpose of this study was to determine the feasibility, safety and preliminary efficacy of a telehealth supervised exercise programme in patients with advanced melanoma receiving checkpoint inhibitor therapy. The study demonstrated that the telehealth exercise programme met the feasibility criteria and was safe with no severe or life-threatening adverse events. Preliminary efficacy analysis showed that the programme significantly improved patients' physical function while maintaining their quality of life.
Article
Oncology
Michael Friedlander, Linda Mileshkin, Janine Lombard, Sophia Frentzas, Bo Gao, Michelle Wilson, Tarek Meniawy, Sally Baron-Hay, Karen Briscoe, Nicole McCarthy, Christos Fountzilas, Andres Cervantes, Ruimin Ge, John Wu, Alexander Spira
Summary: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in previously treated advanced solid tumours. The study showed that pamiparib plus tislelizumab demonstrated a variable level of antitumour activity in patients with advanced solid tumours, with the highest ORR observed in triple-negative breast cancer cases.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Aaron B. Beasley, Daniel P. de Bruyn, Leslie Calapre, Zeyad Al-Ogaili, Timothy W. Isaacs, Jacqueline Bentel, Anna L. Reid, Roy S. Dwarkasing, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Erwin Brosens, Annelies de Klein, Fred K. Chen, Emine Kilic, Elin S. Gray
Summary: This study demonstrates the potential of ctDNA monitoring as a biomarker for the early detection of metastasis and therapeutic response in uveal melanoma patients. It shows that ctDNA levels are predictive of overall survival and may be used for monitoring treatment response.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
John Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long
Summary: Nivolumab is an effective and well-tolerated adjuvant treatment for patients with resected stage IIB/C melanoma.
Article
Oncology
Sophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy
Summary: This study reported the preliminary results of combining Ociperlimab and Tislelizumab in the treatment of advanced solid tumors. The findings demonstrated that this combination therapy was well tolerated and showed some anti-tumor activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Obstetrics & Gynecology
Andrew Fantoni, Tarek Meniawy, Paul A. Cohen, Michelle McMullen
Summary: Improving education and information systems in Western Australia has led to increased somatic BRCA testing rates for patients with HGSOC.
GYNECOLOGIC ONCOLOGY REPORTS
(2023)
Meeting Abstract
Oncology
Aesha Gandhi, John Taylor, Michael Morici, Anna Reid, Tarek Meniawy, Muhammad Adnan Khattak, Elin Gray, Michael Millward, Pauline Zaenker
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
